20-NOV-2024 6:10

MMYEL ACCRUAL REPORT - Open and Recently Closed Studies

SWOG/
Support		 STUDY R
E
G		 O
P
E
N		 ARM ACCR.
GOAL		 TOTAL
REGS.		 REGS.
LAST
12
Month		 REGS.
LAST
6
Month		 REGS.
LAST
3
Month		 REGS.
LAST
30
DAYS		 REGS.
LAST
7
DAYS		 DATE OF
FIRST
REG.		 # of
ACT.
INSTs		 # of
CURR
IRBs
SWOG S1803-MM, Maintenance, Len vs Len/Dara 1 Y 0 Screening 1420 1383 242 140 75 30 4 08/13/2019 329 128
            1383 242 140 75 30 4      
 
    2 Y 1 Lenalidomide   636 108 64 34 13 1 08/13/2019    
        2 Lenalidomide + Daratumumab   627 110 63 32 13 1      
            1263 218 127 66 26 2      
 
    3 Y 3 Stop vs Continue Treatment   219 70 36 20 5 1 08/13/2019    
            219 70 36 20 5 1      
 
  S2005-WM, Prev. Untreated, I/R +/- Venetoclax 1 Y 1 I+R 92 4 4 3 2 2 0 01/05/2022 83 28
        2 I+R+Venetoclax   1 0 0 0 0 0      
        3 V+R   4 4 3 1 1 0      
            9 8 6 3 3 0      
 
  S2209-MM, Newly Dx, VRd-R->R v DRd-R->R v DRD-DR->D 1 Y 1 VRD-R 510 16 15 8 5 3 1 10/12/2023 220 81
        2 DRD-R   16 16 8 4 1 0      
        3 DRD-DR   17 15 9 6 2 0      
            49 46 25 15 6 1      
 
  S2213-AL Amyloidosis, Newly Dx, Dara-VCD v ASCT 1 Y 0 Induction 338 5 5 5 3 1 0 07/01/2024 114 36
            5 5 5 3 1 0      
 
    2 Y 1 Dara-VCD   1 1 1 1 1 0 07/01/2024    
            1 1 1 1 1 0      
 
Yes EAA181-Myel, Newly Dx, DRd=>DRd+/-Btz=>DR (EQUATE) 0 E Total Registrations   50 11 4 4 0 0 05/27/2021 207 81
            50 11 4 4 0 0      
 
    1 E Total Registrations   37 9 2 2 0 0 05/27/2021    
            37 9 2 2 0 0      
 
    2 E Total Registrations   27 14 8 4 0 0 05/27/2021    
            27 14 8 4 0 0      
 
No EAA173-MYEL, SMM, Rd +/- Daratumumab 0 E Total Registrations   74 19 7 3 1 0 01/08/2020 242 101
            74 19 7 3 1 0      
 
    1 E Total Registrations   35 10 6 3 1 0 01/08/2020    
            35 10 6 3 1 0      
 

20-NOV-2024 6:10

MMYEL Open Studies with No Registrations

Study Registration/Phase Open Date # of
ACT.
INSTs		 # of
CURR
IRBs
S2005 WM, Prev. Untreated, I/R +/- Venetoclax 2 Crossover 24-Jun-21 83 28
S2213 AL Amyloidosis, Newly Dx, Dara-VCD v ASCT 3 Maintenance 01-Dec-23 114 36